Resilient Pharmaceuticals

Resilient Pharmaceuticals, formerly known as Lykos Therapeutics and before that as the MAPS Public Benefit Corporation (MAPS PBC), is a public benefit corporation (PBC) developing MDMA ("ecstasy") for potential medicinal use. It was founded and is part-owned by the non-profitMultidisciplinary Association for Psychedelic Studies (MAPS). MAPS PBC was founded in 2014 and was renamed to Lykos Therapeutics in January 2024, then to Resilient Pharmaceuticals in August 2025.